Alzamend Neuro, Inc. (ALZN)
Market: NASD |
Currency: USD
Address: 3480 Peachtree Road NE
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Show more
📈 Alzamend Neuro, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$180.00
-
Upside/Downside from Analyst Target:
5,860.26%
-
Broker Call:
2
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
50-100%
-
Revenue Growth Range (1Y):
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2025 |
- |
$0.111111 |
- |
2025-05-12 |
- |
Stock split |
|
Total Amount for 2025: $0.111111 |
| 2024 |
- |
$0.100000 |
- |
2024-07-16 |
- |
Stock split |
|
Total Amount for 2024: $0.100000 |
| 2023 |
- |
$0.066667 |
- |
2023-10-31 |
- |
Stock split |
|
Total Amount for 2023: $0.066667 |
📅 Earnings & EPS History for Alzamend Neuro, Inc.
| Date | Reported EPS |
|---|
| 2025-09-09 (estimated upcoming) | - |
| 2025-09-08 (estimated upcoming) | - |
| 2025-07-28 (estimated upcoming) | - |
| 2025-07-27 (estimated upcoming) | - |
| 2025-03-22 | - |
| 2025-03-10 | -0.19 |
| 2024-12-11 | -0.38 |
| 2024-09-11 | -1.25 |
| 2024-09-10 | -1.25 |
| 2024-07-30 | -13.35 |
| 2024-07-29 | -13.35 |
| 2024-03-25 | -0.38 |
| 2024-03-24 | -0.38 |
| 2023-12-15 | -0.44 |
| 2023-12-14 | -0.44 |
| 2023-09-13 | -0.04 |
| 2023-09-12 | -0.04 |
| 2023-07-27 | -0.03 |
| 2023-07-26 | -0.03 |
| 2023-03-15 | -0.06 |
| 2023-03-14 | -0.06 |
| 2022-12-12 | -0.03 |
| 2022-12-11 | -0.03 |
| 2022-09-13 | -0.03 |
| 2022-09-12 | -0.03 |
| 2022-07-19 | -0.04 |
| 2022-07-18 | -0.04 |
| 2022-03-15 | -0.03 |
| 2022-03-14 | -0.03 |
| 2021-12-13 | -0.04 |
| 2021-12-12 | -0.04 |
| 2021-09-13 | - |
| 2021-09-12 | - |
| 2021-07-29 | - |
| 2021-07-28 | - |
📰 Related News & Research
No related articles found for "alzamend neuro".
